Quidel Corp
Uždarymo kaina
10.61 -16.98
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
10.61
Max
11.1
Pajamos | -1.1M -93M |
|---|---|
Pardavimai | 11M 631M |
Pelno marža | -14.725 |
Darbuotojai | 6,500 |
EBITDA | 86M |
Rekomendacijos | Neutralu |
|---|---|
12 mėnesių prognozė | +12.15% upside |
Rinkos kapitalizacija | 129M 847M |
|---|---|
Ankstesnė atidarymo kaina | 27.59 |
Ankstesnė uždarymo kaina | 10.61 |
Quidel Corp Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
Quidel Corp Prognozė
Kainos tikslas
By TipRanks
12.15% į viršų
12 mėnesių prognozė
Vidutinis 12 USD 12.15%
Aukščiausias 12 USD
Žemiausias 12 USD
Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Quidel Corp kainas – Dist per pastaruosius 3 mėnesius.
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę Quidel Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
